Zusammenfassung
Die Arzneitherapie ist das wichtigste Verfahren zur Behandlung von Epilepsien. Maßgebend für die Auswahl von Antiepileptika sind arzneimittelspezifische Variable (Anfallstyp, Nebenwirkungsprofil, Teratogenität, Pharmakokinetik, Interaktionspotenzial, Arzneiformen) und Patienten-abhängige Faktoren (Alter, Geschlecht, Komedikation, Begleitkrankheiten, genetischer Hintergrund) (McCorry et al. 2004, Glauser et al. 2006).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. for the Gabapentin Diabetic Neuropathy Study Group (1998): Gabapentin for the sympto- matic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280:1831-1836.
Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD (2007): Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizu- res. Epilepsia 48: 1308-1317.
Beydoun A (1999): Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 40 (Suppl 6): S13-S16.
Brodie MJ (2004): Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 Suppl 6: 19-27.
Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ (2007): Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408.
Chong MS, Hester J (2007): Diabetic painful neuropathy. Current and future treatment options. Drugs 67: 569-585.
Costa J, Fareleira F, Ascenäo R, Borges M, Sampaio C, Vaz-Carneiro A (2011): Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52: 1280-1291.
Devinsky O (2011): Sudden, unexpected death in epilepsy. N Engl J Med 365: 1801-1811.
Dooley M, Plosker GL (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871-893.
Eisenberg E, River Y, Shifrin A, Krivoy N (2007): Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67: 1265-1289.
European Medicines Agency (2004): Europäischer öffentlicher Beurteilungsbericht (EPAR) Lyrica. Scientific discussion. Internet: www.emea.europa.eu/humandocs/ PDFs/EPAR/lyrica/084504en6.pdf
Finnerup NB, Sindrup SH, Jensen TS (2010): The evidence for pharmacological treatment of neuropathic pain. Pain 150: 573-581.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee (2004): Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45: 401-409.
Gamble CL, Williamson PR, Marson AG (2006): Lamotrigine versus carbamazepine mo- notherapy for epilepsy. Cochrane Database Syst Rev 25(1):CD001031.
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T (2006): ILAE Treatment Guidelines: Evidence- based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47: 1094-1120.
Goa KL, Ross SR, Chrisp P (1993): Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152-176.
Groß;-Selbeck G (1995): Treatment of „benign" partial epilepsies of childhood, including atypical forms. Neuropediatrics 26: 45-50.
Hitiris N, Brodie MJ (2006): Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 19: 175-180.
Holmes D (2012): NICE epilepsy guidance „may be detrimental to patient care". Lancet 379: 399.
Jette NJ, Marson AG, Kadir ZA, Hutton JL (2000): Topiramate for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2: CD001417.
Kassenärztliche Bundesvereinigung (2007): Wirkstoff AKTUELL. Pregabalin (Lyrica® Hartkapseln).Internet: www.kbv.de/publikationen/116.html
Koch MW, Polman SK (2009): Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453.
Kwan P, Sander JW (2004): The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 75: 1376-1381.
LaRoche SM, Helmers SL (2004): The new antiepileptic drugs: scientific review. JAMA 291: 605-614.
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004): The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 101: 9861-9866.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007a): The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000-1015.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007b): The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet 369: 1016-1026.
McCorry D, Chadwick D, Marson A (2004): Current drug treatment of epilepsy in adults. Lancet Neurol 3: 729-735.
Molgaard-Nielsen D, Hviid A (2011): Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305: 1996-2002.
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999): Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabe- tic peripheral neuropathy pain. Arch Intern Med 159: 1931-1937.
National Institute for Health and Clinical Excellence (NICE) (2012): The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. January 2012, NICE clinical guideline 137. Internet: www.nice.org.uk/page.aspx?o=CG020NICEguideline
Perucca E, Yasothan U, Clincke G, Kirkpatrick P (2008): Lacosamide. Nat Rev Drug Discov 7: 973-974.
Shorvon SD (2009): Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 50 Suppl 3: 93-130.
Weil S, Deppe C, Noachtar S (2010): Behandlung von Frauen mit Epilepsie. Dtsch Ärztebl 107: 787-793.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Medizin Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2012). Antiepileptika. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-29242-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29241-5
Online ISBN: 978-3-642-29242-2
eBook Packages: Medicine (German Language)